Zevra Therapeutics develops and sells treatments for rare diseases, including MIPLYFFA for Niemann Pick disease type C. ZVRA reports earnings on Tue, Nov 3, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 7 | Guggenheim | Target lowered | Buy | |
| Aug 6 | Citizens | Maintained | Buy | |
| Jul 27 | Canaccord Genuity | Target lowered | Buy | |
| Jul 27 | Guggenheim | Target lowered | Buy | |
| Jul 27 | BTIG | Target lowered | Buy |
Whale Options Flow
90DNo whale options trades in ZVRA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZVRA is in one of them and how their past ZVRA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ZVRA in an article yet. Here's the latest on the wider market.
About Zevra Therapeutics
Zevra Therapeutics develops and sells medicines for rare diseases. Its main approved products are MIPLYFFA, an oral treatment for Niemann Pick disease type C, and OLPRUVA, used to help manage urea cycle disorders in adults and children. The company also has candidates in clinical development, including celiprolol for vascular Ehlers Danlos syndrome. Its products are sold mainly to patients and providers in the United States, and MIPLYFFA is also made available to patients in parts of Europe through an access program. The company is based in Boston, Massachusetts.
- Headquarters
- Boston, MA